{"id":"memantine-oral-tablet","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Constipation"},{"rate":"3-5","effect":"Confusion"},{"rate":"2-4","effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL807","moleculeType":"Small molecule","molecularWeight":"179.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Memantine blocks the NMDA receptor ion channel in a use-dependent manner, allowing it to preferentially inhibit pathological overactivation of glutamate signaling while preserving normal synaptic transmission. This mechanism reduces excitotoxicity and neuronal damage associated with excessive calcium influx. It is used to slow cognitive decline in moderate to severe Alzheimer's disease by protecting neurons from glutamate-mediated injury.","oneSentence":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamatergic neurotransmission in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:17.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT04302870","phase":"PHASE2, PHASE3","title":"Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-02-27","conditions":"Motor Neuron Disease, Amyotrophic Lateral Sclerosis","enrollment":1150},{"nctId":"NCT07417670","phase":"PHASE4","title":"Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Carnot Laboratories","startDate":"2024-10-04","conditions":"Alzheimer Disease","enrollment":105},{"nctId":"NCT05564169","phase":"PHASE3","title":"Masitinib in Patients With Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-06","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT06275035","phase":"PHASE3","title":"Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-02-22","conditions":"Neurocognitive Dysfunction","enrollment":101},{"nctId":"NCT06679387","phase":"PHASE2","title":"\"The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients\"","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-10-30","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":80},{"nctId":"NCT06594172","phase":"PHASE2","title":"Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2024-09-10","conditions":"Radiation Disease, Cognitive Impairment, Drug Effect","enrollment":67},{"nctId":"NCT03670095","phase":"PHASE1","title":"Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2018-08-28","conditions":"Healthy","enrollment":64},{"nctId":"NCT01872598","phase":"PHASE3","title":"Masitinib in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AB Science","startDate":"2012-01","conditions":"Alzheimer Disease","enrollment":721},{"nctId":"NCT02580305","phase":"PHASE2","title":"SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study","status":"COMPLETED","sponsor":"Suven Life Sciences Limited","startDate":"2015-09","conditions":"Alzheimer's Disease","enrollment":564},{"nctId":"NCT02118727","phase":"PHASE2","title":"Therapy in Amyotrophic Lateral Sclerosis (TAME)","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-11-07","conditions":"Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia","enrollment":89},{"nctId":"NCT05430867","phase":"PHASE4","title":"Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-07-01","conditions":"Treatment, Efficacy, Safety","enrollment":150},{"nctId":"NCT05015595","phase":"PHASE3","title":"Memantine for Refractory OCD Patients","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2021-09-01","conditions":"Obsessive-Compulsive Disorder","enrollment":20},{"nctId":"NCT04417543","phase":"PHASE1","title":"Effect of Memantine on Cognitive Impairment in Patients With Epilepsy","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-10-01","conditions":"Epilepsy","enrollment":100},{"nctId":"NCT01458470","phase":"PHASE2","title":"A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2011-09","conditions":"Huntington Disease","enrollment":19},{"nctId":"NCT03247218","phase":"PHASE2","title":"A Phase - IIa - IIb, Trial to Study the Safety, Tolerability and Efficacy of Memantine as a Long-term Treatment of SCD","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","startDate":"2018-02-02","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT02553928","phase":"PHASE4","title":"Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2015-10","conditions":"Alzheimer Dementia (AD)","enrollment":62},{"nctId":"NCT03121820","phase":"PHASE1","title":"Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2016-10-11","conditions":"Bioequivalence, AUC, Cmax, Pharmacokinetics","enrollment":18},{"nctId":"NCT02079246","phase":"PHASE3","title":"Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2014-04-07","conditions":"Alzheimer's Disease","enrollment":1463},{"nctId":"NCT00294554","phase":"NA","title":"Memantine for Treatment of Cognitive Impairment in Patients With Parkinson's Disease and Dementia","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2006-04","conditions":"Parkinson's Disease, Cognitive Impairment, Dementia","enrollment":20},{"nctId":"NCT02615847","phase":"PHASE2","title":"Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2015-08","conditions":"Sickle Cell Disease","enrollment":9},{"nctId":"NCT03168997","phase":"PHASE4","title":"Memantine Treatment in Alzheimer's Disease Patients","status":"UNKNOWN","sponsor":"Wei Cuibai","startDate":"2017-07-15","conditions":"Alzheimer Disease","enrollment":222},{"nctId":"NCT02570581","phase":"PHASE1","title":"MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2014-06","conditions":"Healthy","enrollment":16},{"nctId":"NCT01052662","phase":"PHASE2, PHASE3","title":"Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2009-10","conditions":"Opioid Dependence","enrollment":87},{"nctId":"NCT00411398","phase":"PHASE3","title":"A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder","status":"COMPLETED","sponsor":"State University of New York - Upstate Medical University","startDate":"2006-12","conditions":"General Anxiety Disorder, Social Anxiety Disorder","enrollment":15},{"nctId":"NCT00235716","phase":"PHASE3","title":"A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2007-08","conditions":"Alzheimer's Disease","enrollment":613},{"nctId":"NCT02136823","phase":"NA","title":"Impact of Persistent Conductances on Motor Unit Firing in SCI","status":"UNKNOWN","sponsor":"Shirley Ryan AbilityLab","startDate":"2009-06","conditions":"Chronic Spinal Cord Injury","enrollment":50},{"nctId":"NCT00857649","phase":"PHASE3","title":"Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2003-12","conditions":"Alzheimer's Disease","enrollment":369},{"nctId":"NCT00857233","phase":"PHASE3","title":"Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease","status":"TERMINATED","sponsor":"H. Lundbeck A/S","startDate":"2004-06","conditions":"Alzheimer's Disease","enrollment":297},{"nctId":"NCT00586573","phase":"PHASE4","title":"Open-Label Pilot Study of Namenda in Adult Subjects With ADHD and ADHD NOS","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-03","conditions":"ADHD","enrollment":34},{"nctId":"NCT00594737","phase":"PHASE3","title":"Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia","status":"COMPLETED","sponsor":"Tiffany Chow, MD","startDate":"2007-10","conditions":"Frontotemporal Dementia","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Memantine","pioglitazone","hippocampal avoidance whole-brain radiotherapy (HA-WBRT)","Namenda","Namenda XR"],"phase":"marketed","status":"active","brandName":"Memantine Oral Tablet","genericName":"Memantine Oral Tablet","companyName":"First Affiliated Hospital Xi'an Jiaotong University","companyId":"first-affiliated-hospital-xi-an-jiaotong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamatergic neurotransmission in the brain. Used for Moderate to severe Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2000-10-11T00:00:00.000Z","mah":"Takeda Pharma A/S","brand_name_local":"Glustin","application_number":"EMEA/H/C/000286"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2003-10-16T00:00:00.000Z","mah":"ABBVIE","brand_name_local":"NAMENDA","application_number":"NDA021487"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2006-07-28T00:00:00.000Z","mah":"CHEPLAPHARM Arzneimittel GmbH","brand_name_local":"Competact","application_number":"EMEA/H/C/000655"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2007-01-08T00:00:00.000Z","mah":"CHEPLAPHARM Arzneimittel GmbH","brand_name_local":"Tandemact","application_number":"EMEA/H/C/000680"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2007-12-11T00:00:00.000Z","mah":"Takeda Pharma A/S","brand_name_local":"Glubrava","application_number":"EMEA/H/C/000893"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-06-21T00:00:00.000Z","mah":"ABBVIE","brand_name_local":"NAMENDA XR","application_number":"NDA022525"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2011-07-22T00:00:00.000Z","mah":"Ratiopharm GmbH","brand_name_local":"Pioglitazone ratiopharm GmbH","application_number":"EMEA/H/C/002369"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2011-07-22T00:00:00.000Z","mah":"Ratiopharm GmbH","brand_name_local":"Pioglitazone ratio","application_number":"EMEA/H/C/002370"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2011-07-22T00:00:00.000Z","mah":"Ratiopharm GmbH","brand_name_local":"Pioglitazone ratiopharm","application_number":"EMEA/H/C/002260"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2011-09-23T00:00:00.000Z","mah":"Teva Pharma B.V.","brand_name_local":"Pioglitazone Teva Generics","application_number":"EMEA/H/C/002448"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2012-03-09T00:00:00.000Z","mah":"Vaia S.A.","brand_name_local":"Sepioglin","application_number":"EMEA/H/C/002021"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2012-03-15T00:00:00.000Z","mah":"Actavis Group PTC ehf","brand_name_local":"Pioglitazone Actavis","application_number":"EMEA/H/C/002324"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2012-03-15T00:00:00.000Z","mah":"Actavis Group PTC ehf","brand_name_local":"Glidipion (previously Pioglitazone Actavis Group)","application_number":"EMEA/H/C/002558"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2012-03-21T00:00:00.000Z","mah":"Krka, d.d., Novo mesto","brand_name_local":"Pioglitazone Krka","application_number":"EMEA/H/C/002453"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2012-03-21T00:00:00.000Z","mah":"Krka, d.d., Novo mesto","brand_name_local":"Paglitaz","application_number":"EMEA/H/C/002309"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2012-03-21T00:00:00.000Z","mah":"Accord Healthcare S.L.U.","brand_name_local":"Pioglitazone Accord","application_number":"EMEA/H/C/002277"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2012-03-26T00:00:00.000Z","mah":"Teva Pharma B.V.","brand_name_local":"Pioglitazone Teva Pharma","application_number":"EMEA/H/C/002410"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2012-03-26T00:00:00.000Z","mah":"Teva B.V.","brand_name_local":"Pioglitazone Teva","application_number":"EMEA/H/C/002297"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":"ALPHAPHARM","brand_name_local":"PIOGLITAZONE","application_number":"ANDA076799"}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}